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Abstract
Previous Ussing chamber measurements of secretagogue-pro-
voked changes in short circuit current in rectal suction biopsies
of cystic fibrosis (CF) patients showed that in a minority of
patients chloride secretion in response to cholinergic agonists is
reduced but not completely absent. To assess a possible rela-
tionship between this phenomenon and both the genotype and
the phenotype, we performed Ussing chamber experiments on
rectal suction biopsies of 51 CF patients. The CF mutation was
identified in 89 out of 102 CF alleles. No apparent chloride
secretion was found in 30 CF patients (group I). Low residual
chloride secretion was found in 11 CF patients (group II),
while a relatively high residual secretion appeared in 10 CF
patients (group III). Pancreatic function was preserved more
frequently in CF patients displaying residual secretion: 0% in
group I, 27% in group II, and 60% in group III (P < 0.001). The
age at diagnosis (mean±SEM) in group III (18.4±6.6) was
significantly different from group I (1.2±0.4, P < 0.01) and
group 11 (3.5±1.4, P = 0.05). Residual chloride secretion was
found in some of the 28 dF508 homozygous patients (three in
group II, and one in group III), disclosing that other factors
than the CF gene defect itself affect the transepithelial chloride
transport. The age at diagnosis correlates significantly with the
magnitude of the secretory response, even within the dF508
homozygous patients (r = 0.4, P < 0.05). We conclude that
residual chloride secretion in CF is the pathophysiological
basis of preserved pancreatic function and delayed presentation
of the disease, which is not exclusively determined by the CF
genotype. (J. Clin. Invest. 1994. 93:461-466.) Key words: cys-
tic fibrosis * intestinal secretion * genotype * phenotype * muta-
tional analysis
Introduction
In cystic fibrosis (CF)' conductive chloride transport is defec-
tive in epithelial tissues. This results in viscous secretions asso-
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1. Abbreviations used in this paper: CF, cystic fibrosis; CFTR, cystic
fibrosis transmembrane regulator; DIOS, distal intestinal obstruction
syndrome; FVC, forced vital capacity; FEV 1, forced expiratory volume
in 1 s; Isc, short circuit current; M, mucosal bath; S, serosal bath.
ciated with pulmonary infections, malabsorption, and intes-
tinal obstruction (1-3). A major gene defect (dF508) repre-
sents - 70% of the gene mutations in CF (4, 5). The product
of the CF gene, the cystic fibrosis transmembrane conductance
regulator (CFTR), functions itself as a chloride channel and
may therefore be held responsible for the known defect in trans-
epithelial chloride transport in CF (6, 7). In most CF patients,
including dF508, the mutation in the CF gene results in a mis-
localization rather than dysfunctioning of the CFTR-chloride
channel (8-13). In a smaller group of CF patients, however,
the channel protein is properly inserted into the apical mem-
brane ofthe epithelial cells but is functionally impaired or inac-
tive (8, 14).
The severity ofthe disease ranges widely. Homozygosity for
the dF508 mutation was found to correlate with pancreatic
insufficiency (15-18), early diagnosis (16-19), poor lung
function ( 16, 18), chronic pseudomonas colonization ( 18),
and high mortality ( 18 ). A relationship between clinical mani-
festations of the disease and the genotype implies that abnor-
malities in transepithelial electrolyte transport may vary with
specific mutations. More than 230 different CF mutations have
now been described (20).
In contrast to other epithelia of CF patients, intestinal tis-
sues not only show defective chloride secretion in response to
cAMP-linked secretagogues, but also in response to Ca-linked
secretagogues, including cholinergic stimulation (21-23). As
shown by electrophysiological studies in isolated colonic crypts
(24) and in colonic epithelial cell lines (25, 26), a major stimu-
lating effect of carbachol is on the basolateral potassium con-
ductance, creating an increased driving force for chloride exit
through CFTR-chloride channels in the apical membrane (24,
25). Furthermore, the protein kinase C component of the car-
bachol response may activate the CFTR-chloride channel by
direct phosphorylation (27-29). However, in contrast to their
prominent role in other epithelial tissues in the intestine, the
contribution of calcium-activated chloride channels (different
from CFTR) to the apical chloride secretion is negligible (26,
30, 31).
Recently, we demonstrated that in a minority of CF pa-
tients chloride secretion provoked by cholinergic agonists was
reduced but not completely absent (32). This residual transepi-
thelial chloride transport could help to explain the clinical het-
erogeneity among CF patients (32, 33). To assess a possible
relationship between this phenomenon and both the genotype
and the phenotype, we extended our Ussing chamber experi-
ments on rectal suction biopsies to a largergroup ofCF patients
and found a relationship between residual chloride secretion
and both a milder phenotype and the CF genotype.
Methods
Patients. This study was approved by the Hospital Medical Ethical
Committee and by patients or their parents by written informed con-
Residual Intestinal Chloride Secretion in Cystic Fibrosis 461
J. Clin. Invest.
©3 The American Society for Clinical Investigation, Inc.
0021-9738/94/02/0461/06 $2.00
Volume 93, February 1994, 461-466
sent. During the study period of 2 yr, 173 pediatric and adult CF pa-
tients (78 male, 95 female) with a mean age of 14.8 yr (range, 0.1-69.9
yr) who regularly visited our University Hospital were asked to have a
rectal suction biopsy taken. Supplemented with 2 patients homozygous
for the G542X mutation who came from another clinic, a total of 51
CF patients (25 male, 26 female) with a mean age of 16.5 yr (range,
0.1-69.9 yr) were enrolled in the study. Each patient's diagnosis was
confirmed by at least two abnormal sweat tests (> 70 mmol sodium/
liter or > 60 mmol chloride/liter).
The medical records were evaluated for a history of meconium
ileus, pancreatic insufficiency, distal intestinal obstruction syndrome
(DIOS), chronic pseudomonas colonization, and nasal polyp extrac-
tion. Pancreatic sufficiency was defined as normal fecal chymotrypsin
(> 6.3 U/g) and fat content values (< 5 g/d) without pancreatic en-
zyme supplements. The date of onset of chronic pseudomonas coloni-
zation was defined as the date ofthe first isolation ofat least two consec-
utive sputum samples from which pseudomonas could be cultured.
Records of forced vital capacity (FVC) and forced expiratory volume
in 1 s (FEVl ) were measured and expressed as a percentage of pre-
dicted normal values for age, height, and sex. The results of each pa-
tient's most recent pulmonary function tests were used. At the end of
the 2-yr study period, each subject was assigned a clinical score with the
use of the Shwachman and Kulczycki clinical scoring system as modi-
fied by Doershuk et al. (34). This is based on general activity, pulmo-
nary physical findings, growth and nutrition, and x-ray findings, result-
ing in a score from 20 (worst) to 100 (best). Furthermore, each pa-
tient's age at diagnosis and maximal derived (current age at the end of
the 2-yr study period or age at death) were recorded. Four patients died
during the study period.
Electrophysiological study. The procedure of short circuit current
(Isc) measurements on rectal tissue has been described earlier (32).
Briefly, fresh rectal suction biopsies were mounted in an Ussing
chamber with an exposed area of 1.13 mm2. After stabilization of the
basal Isc, various substances were added to the mucosal (M) and/or
serosal (S) baths: (a) glucose ( 10-2 mol/liter) was added to M and S;
(b) to reduce the contribution ofelectrogenic sodium absorption to the
Isc, specific sodium channels were blocked by amiloride ( 10-4 mol/
liter) added to M; (c) the endogenous prostaglandin synthesis that is
possibly linked to cAMP-mediated chloride secretion was inhibited by
adding indomethacin ( 10-5 mol/liter) to M and S; (d) by adding car-
bachol (10-4 mol/liter) to S the cholinergic activation of chloride se-
cretion was initiated. All chemicals were obtained from Sigma Chemi-
cal Co. (St. Louis, MO).
To investigate the reproducibility of the experiments without in-
creasing discomfort for the participants, we analyzed two biopsy speci-
mens simultaneously in a subgroup of 18 CF patients.
The mean carbachol-provoked change in ISC values (±SEM) was
35.1±2.6 MA/cm2 in 47 healthy volunteers < 18 yr old, and 22.4±4.3
MA/cm2 in 8 subjects > 18 yr old. This difference tended to be statisti-
cally significant (P = 0.07, Mann-Whitney; Pearson's correlation be-
tween age and ISC: r = -0.23, P = 0.10). The inward current provoked
by carbachol in controls (ISC positive; Fig. I ) reflects transcellular chlo-
ride transport (serosa to mucosa) through the Na-K-Cl cotransporter
in the basolateral membrane and the CFTR-chloride channel in the
apical membrane (32). The observed magnitude of this response in
controls may well be underestimated by underlying potassium secre-
tion (32).
In the majority ofCF patients, hereafter classified as group I, carba-
chol induces only an outward current response (ISC negative; Fig. 1) .
Most plausibly this reversed current results from apical potassium se-
cretion that is unmasked in the case of absent or largely reduced chlo-
ride secretion (32, 35, 36). The carbachol-provoked ISC changes in CF
patients, and possibly also in controls, may therefore be the net result of
two opposite currents. In a subclass of CF patients, usually after a
negative peak response, a separate and small positive peak response
(i.e., inward current) was observed (Fig. 1, groups II and III). To facili-
tate comparison with the data from group I and controls, the net maxi-
mal change in Isc was defined as the sum of the negative and positive
peak responses (Fig. 1, neg + pos). This calculated response was either
negative (low residual secretion, group II) or positive (high residual
secretion, group III).
DNA analysis. We analyzed for the Ri 17H, R347P, A455E, 621
+ IG -- T, d1507, dF508, 1717 - IG -- A, V520F, G542X, S549N,
S5491, G551D, R553X, R1162X, S1251N, W1282X, and N1303K
mutations by PCR amplification of the appropriate exon sequences.
Specific mutation detection involved the use of allele-specific oligonu-
cleotides or amplification refractory mutation system (ARMS) (5, 37,
38). In addition, PCR-amplified exons 10 and 11, which are known to
contain several mutations, were subjected to single strand conforma-
tion polymorphism as an aspecific screen for sequence alterations in
these exons (39).
Statistics. Differences were considered significant if P < 0.05. The
Pearson's correlation coefficient was calculated between short circuit
current and age at diagnosis. Comparing the maximal derived age, a
survival analysis was performed using the log-rank test for testing signi-
ficancy. All statistical tests were two tailed.
Results
The reduction in basal Isc in response to amiloride
(mean±SEM) in CF patients (-9.2±1.6 ,gA/cm2; n = 51 ) was
not different from age-matched control values (-8.7±1.5 /IA/
cm2; n = 50). This outcome strengthens our previous conclu-
sion that the strong increase in apical sodium channel activity
seen in CF airway does not occur in rectal epithelium (32).
Three groups of CF patients could be distinguished on the
basis ofthe electrophysiological response to carbachol. Group I
consisted of 30 patients who failed to demonstrate residual in-
testinal chloride secretion. In group II, 11 patients showed low
residual chloride secretion, and group III consisted of 10 pa-
tients displaying high residual chloride secretion. From group I
to III, the CF patients had a milder clinical presentation of the
disease. This is demonstrated by the age at diagnosis, which is
significantly higher in CF patients with high residual secretion
compared with groups I and II (Table I). The difference in the
age at diagnosis between groups I and II indicates that even CF
patients with a low residual secretion are less affected by the
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Figure 1. Different patterns of carbachol-induced Isc responses in
rectal epithelium in the presence of amiloride and indomethacin.
Additions are marked by arrows. For concentrations and site of addi-
tions, see Methods.
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Table I. Characteristics ofCF Patients with a Different Pattern ofCarbachol-induced Changes in Ic
in Rectal Suction Biopsies in the Presence ofAmiloride and Indomethacin
Intestinal chloride secretion
I: No apparent II: Low residual III: High residual
residual secretion secretion secretion
CF patients (n) 30 11 10
Carbachol induced secretion:
Net change in Ic (MA/cm2) -8.8±2.1 -5.8± 1.5 5.2±1.4*
Genotype:
1. dF508/N1303K 2 0 0
2. dF508/dF508 24 3 1
3. dF508/G542X 1 1 0
4. G542X/G542X 0 2 0
5.dF508/A455E 0 1 3
6. A455E/other 0 0 1
7. R553X/other 0 1 0
8. dF508/other 3 3 5
Age at diagnosis (yr) 1.2±0.4 3.5±1.4 18.4±6.6*
Died in study period (n) 2 2 0
Maximal derived age (yr) 14.3±2.0 13.0±2.4 26.9±6.4§
Shwachman score 69.0±4.2 74.1±7.6 74.0±7.0
Pulmonary function:
CF patients (n) 19 8 7
Age (yr) 19.1±1.7 15.4±1.4 33.9±6.8
FVC (% predicted) 68.1±4.2 75.4±10.3 81.8±7.3
FEVI (% predicted) 51.9±5.4 63.9±12.4 58.5±10.7
Pancreatic insufficiency (n [%]) 30 [100] 8 [73] 4 [40]"
Meconium ileus (n [%]) 10 [33] 2 [18] 1 [10]
DIOS (2n [%]) 4 [14] 0 [0] 0 [0]
Pseudomonas colonization (n [%]) 21 [72] 7 [64] 4 [40]
Nasal polyp extraction (n [%]) 9 [31] 1 [9] 3 [30]
Values are expressed as mean±SEM unless otherwise indicated. Differences of group III from groups I or II: *I, II:
= 0.05, Mann-Whitney; § I: P < 0.05, II: P = 0.06, log-rank test; 1I P < 0.001, Fisher's exact test.
disease (P = 0.07, Mann-Whitney) than those without. The
proportion of pancreatic insufficient CF patients decreases sig-
nificantly from groups I to III (Table I). Additionally, the
mean carbachol-provoked Isc response in the 9 pancreatic suf-
ficient patients (3 of group II and 6 of group III) was signifi-
cantly higher (2.6±2.5 MA/cm2) than in the other 42 pancre-
atic insufficient patients (-7.1±1.6 MA/cm2; P < 0.01, Mann-
Whitney). The proportion ofCF patients with other intestinal
symptoms (meconium ileus and DIOS) was also lower in
group III, but the differences were not significant (Table I).
The prevalences of pseudomonas colonization, and nasal po-
lyp extraction are summarized in Table I. Comparing the lung
functions and Shwachman scores (Table I), as well as the previ-
ously mentioned prevalence of pancreatic status, DIOS, pseu-
domonas colonization, and nasal polyp extraction, we have to
take into account that the time for CF patients of group III to
develop more advanced disease was longer. This is demon-
strated by their average maximal derived age, which was signifi-
cantly higher in group III than in the other groups (Table I).
The distribution of genotypes among the three groups de-
fined on the basis of electrophysiological response is indicated
in Table I. Of all genotypes the dF508 homozygous patients are
most frequent (55%). Most, but not all, ofthem lack a positive
Isc component in their response (Table I). CF patients carrying
P < 0.001; I: P < 0.01, II: P
one A455E mutation are predominantly found in group III.
Considering the variability in Isc responses, even within the
dF508 homozygous patient group, we also asked ourselves
whether or not a relationship existed between the magnitude of
the secretory response and the phenotypic expression of the
disease. A positive correlation (r = 0.37, P < 0.01) was found
between age at diagnosis and the net Isc response (Fig. 2). This
correlation was also significant (r = 0.40, P < 0.05) for the
dF508 homozygous patients.
Two CF patients combined dF508 with G542X; one of
these showed low residual secretory activity. The two CF pa-
tients homozygous for the G542X mutation both displayed
low residual secretion (Table I). All CF patients with one
A455E allele showed residual activity (Table I). Compared
with all other genotypes in this study, these CF patients are
diagnosed at a significantly older age, have a higher Isc re-
sponse, have a higher maximal derived age, and are less fre-
quently pancreatic insufficient (Table II).
In 18 CF patients duplicate rectal suction biopsies were
studied. When every first result (Fig. 2, x-axis) equals the re-
sults of the duplicate registration (y-axis), then a line through
zero (fi = intercept =0) with a tangent = 1 can be drawn. In the
equation: Result1 = a Result2 + ,B, the # was -1.5 (not differ-
ent from 0) and the a was 0.7 (not different from 1).
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Figure 2. Correlation between age at diagnosis and Isc measurements
on rectal suction biopsies of CF patients (r = 0.37, P < 0.01). The
correlation was also found in the dF508 homozygous patients (n) (r
= 0.40, P < 0.05). The other genotypes, indicated by numbers, are
explained in Table I. Positive net Isc changes implicate net residual
chloride secretion while a negative response indicates predominant
K+ secretion perhaps blunted by underlying residual CF- secretion.
Discussion
The changes in Isc provoked by carbachol represent the net
result of all electrical charge fluxes through both apical and
basolateral membranes. A positive change in Isc induced by
carbachol in a control biopsy specimen is an indicator for net
electrogenic chloride secretion. However, in most CF patients,
responses to carbachol are characterized by a change in Isc in
Table II. Characteristics ofCF Patients with One A455E
Mutation vs. All Other Tested Mutants
Genotype
1, 2, 3, 4, 7, 8 5 (dF508/A455E)
(see Table 1) 5 (A455E/other)
Patients (n) 46 5
Carbachol induced secretion:
Net change in I, (MA/cm2) -6.4±1.6 3.8±1.7*
Age at diagnosis (yr) 2.7±0.7 26.3±12.4*
Died in study period 4 0
Maximal derived age (yr) 14.5±1.5 35.0±11.4§
Shwachman score 67.0±12.5 71.5±3.4
Pulmonary function:
CF patients (n) 30 4
Age (yr) 18.4±1.2 42.9±9.8
FVC (% predicted) 72.7±4.1 72.5±8.0
FEV1 (% predicted) 57.9±5.1 42.1±7.4
Pancreatic insufficiency (n [%]) 41 [89] 1 [20]"
Meconium ileus (n [%]) 13 [28] 0 [0]
DIOS (n [%]) 4 [9] 0 [0]
Pseudomonas colonization (n [%]) 29 [64] 3 [60]
Nasal polyp extraction (n [%]) 11 [24] 2 [40]
Values are expressed as mean±SEM unless otherwise indicated.
* P < 0.01, * P < 0.05, Mann-Whitney; I P < 0.001, log-rank test;
P < 0.01, Fisher's exact test.
the opposite direction (32). Apparently, this inversed response
reflects potassium secretion through apical potassium chan-
nels, most likely unmasked by the chloride channel defect asso-
ciated with the CF condition (32). In both normal and CF
tissue the magnitude of the chloride and potassium current,
respectively, may well be underestimated when apical potas-
sium channels are also functioning in normal tissue (36) and if
apical chloride channels retain a residual activity in CF cells.
However, the relative magnitude of chloride and potassium
currents for each biopsy is difficult to estimate. First, the small
size of the biopsy as well as the transient character of the
changes in Isc provoked by carbachol prevent accurate assess-
ment of unidirectional 36C1 or 86Rb flux rates. Also, specific
inhibitors of apical chloride channels (i.e., CFTR) or apical
potassium channels are not yet available (31 ). The positive ISC
responses remain representative for residual chloride secretion
while negative Isc responses indicate predominant potassium
secretion, perhaps blunted by underlying residual chloride se-
cretion.
Considering the recent finding that most mutant CFTR is
functionally active but is inappropriately targeted to the
plasma membrane (8-13), one possible reason for a variable
level of residual chloride secretion, in particular among pa-
tients of identical genotype, may be a variable degree of mislo-
cation of the CFTR protein in the enterocytes. Alternatively,
the variability may arise from a variable expression level of
other chloride channel species in the apical membrane, e.g.,
calcium-activated chloride channels, which normally do not
contribute much to the carbachol-provoked changes in Isc in
intestine (26, 30, 31). Furthermore, several missense muta-
tions located in the transmembrane domain ofCFTR are char-
acterized by an incomplete loss of chloride channel function
and may also lead to residual chloride secretion ( 14).
In Table I, we demonstrate a relationship between residual
chloride secretion and clinical parameters. The positive Isc re-
sponses observed in group III CF patients are not the result of
the more advanced mean age in this group, since control values
normally decline with increasing age (see Methods). The high
residual secretion found in these CF patients might very well be
the pathophysiological basis of their milder clinical presenta-
tion, as indicated by the age at diagnosis and the preserved
pancreatic function. The data from from Table I additionally
indicate that, in comparison with groups I and II, and in con-
trast of what could be expected from their higher current age,
CF patients of group III also reach a higher Shwachman score
and have a more preserved lung function. The preserved pul-
monary function in group III suggests that residual chloride
secretion may also occur in airway epithelium. Some ofthe CF
patients (Fig. 2) have a calculated response approaching age-
matched control values. However, the appearance of their re-
sponses was abnormal, due to the (preceding) transient deflec-
tion of the Isc that was never observed in controls.
A more continuous relationship between the Isc and the age
at diagnosis is illustrated in Fig. 2. Even within the group of
dF508 homozygous patients, a positive correlation between the
net Isc response and the age at diagnosis was found. As dis-
cussed above, the variability in phenotypic expression of the
disease within patients of identical CF genotype can be ex-
plained by interindividual differences in the extent of missort-
ing of mutant CFTR or in the expression of other (compensa-
tory) chloride channels. It has been suggested before that ge-
netic factors other than the CF gene may modify the expression
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of the disease ( 17 ). Prediction ofthe clinical prognosis in indi-
vidual CF patients may thus not rely on the CF genotype alone.
The previously described genotype-phenotype relationship
(16-19) implies that the (residual) function of CFTR may
vary with different mutations. In Xenopus oocytes it was dem-
onstrated that the chloride conductance depends on the CF
genotype (9). In this study we demonstrate that most, but not
all, dF508 homozygous patients are found in group I and that
CF patients with one A455E mutation can be found predomi-
nantly in group III. The latter mutation presumably affects the
sorting and/or activity of CFTR to a lesser extent, thus allow-
ing for residual secretion and milder clinical symptoms (Table
II). The A455E mutation was also characterized by others as a
mild mutation associated with preserved pancreatic function
(40). The two dF508/N1303K patients both had pancreatic
insufficiency and failed to show apparent residual chloride se-
cretion. This is in agreement with others who characterized the
N1303K mutation as a severe one (41).
Interestingly, two patients homozygous for the nonsense
mutation G542X had a low residual secretion (in duplicate).
Since in other stop codon mutants noCFTRmRNA was detect-
able (42), the residual chloride secretion in the two homozy-
gous G542X patients most likely results from compensatory
non-CF-affected chloride channel species (26) in the apical
membrane, rather than from the presence of some functional
CFTR.
We conclude that the residual chloride secretion in CF is
the pathophysiological basis of preserved pancreatic function
and delayed presentation of the disease. Compared with
dF508, the A455E mutation can be characterized as a mild
mutation allowing for residual chloride secretion. The occur-
rence of residual chloride secretion in the intestine is not exclu-
sively determined by the CF genotype.
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